Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexmecamylamine

Drug Profile

Dexmecamylamine

Alternative Names: Dexmecamylamine hydrochloride; NIH-11008; S(+)-mecamylamine; S-mecamylamine; TC-5214

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Targacept
  • Developer AstraZeneca; Atacama Therapeutics; Targacept
  • Class Antidepressants; Norbornanes; Small molecules
  • Mechanism of Action Alpha3beta4 nicotinic receptor antagonists; Alpha4beta2 nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperhidrosis
  • Discontinued Hypertension; Major depressive disorder; Overactive bladder; Resistant hypertension

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 19 Jan 2018 Atacama Therapeutics plans a phase II trial for Hyperhidrosis in January 2018 , (NCT03404570)
  • 21 Dec 2017 Phase-II clinical trials in Hyperhidrosis in USA (PO) (NCT03404570)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top